Morningstar

IQVIA Holdings Inc IQV

Morningstar Rating
Unlock
Stock XNYS Rating as of
$259.21 −8.56 (3.20%)
View Full Chart
As of Delayed Price Pre-Open: $258.50 −0.50

Company Report

View Archive

Positive Outlook for Narrow-Moat Iqvia Supported by Durable Demand, AI Innovation, and Execution

Rachel Elfman

Iqvia (formerly QuintilesIMS) is the result of the merger of Quintiles, a leading late-stage contract research organization, and IMS Health, a dominant player in life sciences data and analytics. The combined company has become a leader among contract research organizations, or CROs, and in the life sciences data and analytics industry. As a result of the merger, the company leads in real-world evidence, in which data from sources such as patient records or medical claims can be used to create clinical evidence for regulatory approval.

Read Full Report

Price vs Fair Value

View History
IQV is trading at a LOCK|xPcw?TG premium.
Price
$259.21
Fair Value
LOCK|Gz
Uncertainty
LOCK|wg$t
1-Star Price
LOCK|W.#V
5-Star Price
LOCK|v.>%
Economic Moat
LOCK|>#^%
Capital Allocation
LOCK|g!$>!%

Bulls Say, Bears Say

Bulls

Iqvia's leading position in outsourced clinical trials allows it to create sticky client relationships, further honing clinical and regulatory expertise.

Bears

The company's next-generation solutions could lose traction among clients or fail to gain traction with regulatory bodies.

Show More

News

View All

Articles & Videos

Trading Information

Previous Close Price
$267.77
Day Range
$259.00–264.79
52-Week Range
$154.50–271.80
Bid/Ask
$250.00 / $280.00
Shares Outstanding
164.60M
Market Cap
$42.67B
Volume/Avg
1,408 / 1M

Key Statistics

Price/Earnings (Normalized)
20.79
Price/Sales
2.60
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
2.72%

Company Profile

Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Core
Total Number of Employees
94,000
Website
https://www.iqvia.com

Competitors

Valuation

View More
Metric
IQV
ICLR
FTRE
Price/Earnings (Normalized)
 20.7914.54127.61
Price/Book Value
 6.911.303.10
Price/Sales
 2.601.470.59
Price/Cash Flow
 16.8512.8030.37
Price/Earnings
IQV
ICLR
FTRE

Financial Strength

Metric
IQV
ICLR
FTRE
Quick Ratio
 0.620.920.85
Current Ratio
 0.710.950.96
Interest Coverage
 2.991.530.08
Quick Ratio
IQV
ICLR
FTRE

Profitability

Metric
IQV
ICLR
FTRE
Return on Assets (Normalized)
 7.22%3.91%2.15%
Return on Equity (Normalized)
 34.41%6.87%10.56%
Return on Invested Capital (Normalized)
 12.37%6.21%7.32%
Return on Assets
IQV
ICLR
FTRE

Diagnostics & Research Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Thermo Fisher Scientific Inc
TMO
LOCK|z#xfFx<RLOCK|$>M$223B
 Danaher Corp
DHR
LOCK|sD!q$l?LOCK|?s!$144B
 Agilent Technologies Inc
A
LOCK|^ft^>?BfLOCK|%<$41B
 IDEXX Laboratories Inc
IDXX
LOCK|cr$Dh!?!LOCK|hZ#$41B
 Waters Corp
WAT
LOCK|!KMjwT^LOCK|#?$40B
 Illumina Inc
ILMN
LOCK|bB?^&zhLOCK|@VZxs$32B
 Mettler-Toledo International Inc
MTD
LOCK|LsWWWz>LOCK|?$JSM$27B
 Labcorp Holdings Inc
LH
LOCK|BfWR#QGLOCK|>?%z$26B
 Quest Diagnostics Inc
DGX
LOCK|p$?wy&LOCK|pT<^c$26B

Sponsor Center